SCHEMBL5137962

SCHEMBL5137962

CCCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(CCCC)Cc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.44
CRHR1 P34998 2/20 0.43
TSHR P16473 5/20 0.43
PDE4B Q07343 2/20 0.43
ALDH1A1 P00352 5/20 0.42
KDM4E B2RXH2 4/20 0.42
CYP3A4 P08684 4/20 0.42
HPGD P15428 4/20 0.42
HSD17B10 Q99714 4/20 0.42
ATP4A P20648 1/20 0.40
ATP4B P51164 1/20 0.40
TP53 P04637 1/20 0.40
HSD11B1 P28845 1/20 0.39
BCHE P06276 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL649161 0.97 C5AR1 (0.47) C5AR1CRHR1TSHRPDE4BALDH1A1
Hydrochloric Acid SCHEMBL648480 0.95 C5AR1 (0.46) C5AR1CRHR1TSHRPDE4BALDH1A1
SCHEMBL5134917 0.95 C5AR1 (0.44) C5AR1CRHR1TSHRPDE4BALDH1A1
SCHEMBL5134816 0.94 CRHR1 (0.44) C5AR1CRHR1TSHRALDH1A1KDM4E
SCHEMBL5137501 0.93 C5AR1 (0.43) C5AR1CRHR1TSHRPDE4BALDH1A1
SCHEMBL5136887 0.93 C5AR1 (0.43) C5AR1CRHR1TSHRPDE4BALDH1A1
SCHEMBL5135469 0.93 C5AR1 (0.43) C5AR1CRHR1TSHRPDE4BALDH1A1
SCHEMBL5137489 0.92 C5AR1 (0.48) C5AR1CRHR1TSHRALDH1A1KDM4E
SCHEMBL5138025 0.92 C5AR1 (0.47) C5AR1CRHR1TSHRPDE4BALDH1A1
SCHEMBL5135234 0.92 TP53 (0.47) C5AR1CRHR1TSHRPDE4BALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed